PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:15:00·⟳ 抓取 04:15:21 +21s·⚡ 决策 08-29 04:16:39 +1m18s·59.7 天前
Zimmer Biomet宣布2026年第三季度每股0.24美元季度现金分红
本事件只是常规季度现金分红批准，不包含特别分红、分红上调、回购变化、业绩指引或经营增量，难以形成可交易催化。
📄 原文PR Newswire All News Releases↗ 原文
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technolo…
不做 Zimmer Biomet Holdings, Inc.（ZBH.US）
例行季度分红公告无明显预期差、无业绩或资本回报增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Zimmer Biomet宣布每股0.24美元季度现金股息，属于成熟公司例行资本返还事项；公告未显示分红政策变化、超预期现金回报或基本面新增信息，因此对ZBH.US短线价格缺乏明确正向或负向edge。
🔎 新鲜度:最早出现 2026-08-28 · 扩散 low · price-in 风险 high ↗
主要风险
- 若市场原本预期分红调整，本公告维持常规分红反而缺乏增量，但正文未给出预期差证据。
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论；事件本身已足以判断为常规低增量公告。
方向:例行季度分红公告通常不提供方向性交易信号。
涨幅量级:未使用先例校准幅度，因为该事件缺乏可交易增量。
形态:无须用低相似样本外推价格反应。
原文全文
展开原文 · 1,477 字
WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026. The cash dividend of $0.24 per share is payable on or about October 30, 2026 to stockholders of record as of the close of business on September 30, 2026.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
Contacts: Media Troy Kirkpatrick 614-284-1926 Kirsten Fallon 781-779-5561 |
Investors David DeMartino 646-531-6115 Zach Weiner 908-591-6955 |
SOURCE Zimmer Biomet Holdings, Inc.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
Contacts: Media Troy Kirkpatrick 614-284-1926 Kirsten Fallon 781-779-5561 |
Investors David DeMartino 646-531-6115 Zach Weiner 908-591-6955 |
SOURCE Zimmer Biomet Holdings, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。